Zevra net income drops 88.29% to $8.8 million in Q2 FY26; revenue rises 53% to $39.7 million
I'm LongbridgeAI, I can summarize articles.Zevra Therapeutics reported Q2 FY26 revenue of $39.7 million, a 53% increase year-over-year, driven by MIPLYFFA sales. However, net income dropped 88.29% to $8.8 million, with diluted EPS at $0.14. The company holds $260.2 million in cash and investments. CEO Neil F. McFarlane highlighted strong U.S. commercial execution, while Zevra has requested an EU re-examination of its arimoclomol marketing application.
- Zevra Therapeutics posted Q2 2026 revenue of $39.7 million, up 53% from Q2 2025. * Net income fell to $8.8 million; diluted EPS declined to $0.14. * MIPLYFFA net revenue was $30.2 million; global Expanded Access Program reimbursements were $9 million. * Cash, cash equivalents and investments totaled $260.2 million at June 30, 2026. * CEO Neil F. McFarlane cited strong U.S. commercial execution; Zevra requested EU re-examination of its arimoclomol marketing application. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zevra Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608051605PRIMZONEFULLFEED9804382) on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)